Tumor profiling assay recalled after incorrect result gave wrong therapy recommendation
One MI Cancer Seek tumor mutational profiling assay is recalled because an incorrect test result was provided that indicated the incorrect drug therapy recommendation.
The agency’s classification
FDA (Devices): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 3/5 (High).
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: Rubric level 3 covers risk-of-harm products where injury has not yet been reported; the notice states an incorrect result led to an incorrect drug therapy recommendation, with no injuries reported.
Plain-English summary
MI Cancer Seek, REF MSC000, UDI code (01)00860008613325(21)H5HJHDSXF, serial number H5HJHDSXF, is being recalled. The assay is a single-site test intended to provide tumor mutational profiling for use by qualified healthcare professionals in accordance with professional oncology guidelines. The recall covers 1 unit distributed in New York.
The recall was issued because an incorrect test result was provided that indicated the incorrect drug therapy recommendation. The FDA classified the action as Class II.
The laboratory and treating clinicians should follow the manufacturer's instructions on reviewing the affected result.
The recalled product
- Product
- MI Cancer Seek REF MSC000 UDI Code: (01)00860008613325(21)H5HJHDSXF MI Cancer Seek is a single-site assay intended to provide tumor mutational profiling to be used by qualified healthcare professionals in accordance with professional oncology guidelines for cancer patients…
- Manufacturer
- CARIS LIFE SCIENCES
- Affected units
- 1
Distribution
Related recalls
Same hazard · erroneous results
See all →- HighBeckman Coulter DxC 500i Analyzer Modules Recalled for Software Defect
FDA (Devices) · 2026-08-26
- HighChemistry analyzer control modules recalled over software that may give erroneous results
FDA (Devices) · 2025-12-24
- HighLaboratory automation recalled over unlabelled or mismatched secondary sample tubes
FDA (Devices) · 2025-12-03
- HighBlood lead test kits recalled over mislabeled calibration buttons
FDA (Devices) · 2025-12-03
- HighLaboratory automation recalled over sample tubes with mismatched labels
FDA (Devices) · 2025-12-03
Similar recalls
- HighRayStation 6 Service Pack 1 Radiation Therapy Software Recall
FDA (Devices) · 2020-06-17
- HighSkin cancer aid recalled because it may not meet specifications
FDA (Devices) · 2025-12-03
- ModerateFoundationOne Companion Diagnostic F1CDx Incorrect Claim Display
FDA (Devices) · 2025-06-11
- HighRayStation 6 Radiation Therapy Software Recalled for Dose Calculation Error
FDA (Devices) · 2020-06-17
- HighRayStation 8A Radiation Therapy Software Recalled for Dose Calculation Error
FDA (Devices) · 2020-06-17
- ModerateFoundationOne Companion Diagnostic contains incorrect negative claims
FDA (Devices) · 2025-06-11